NCT04123379 - Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Non-small Cell Lung CancerHepatocellular Carcinoma

Interventions

DRUG

Nivolumab

q4w, dosed twice before surgery and three times following recovery from surgery by injection

DRUG

BMS-813160

300mg oral twice a day for 28 days

DRUG

BMS-986253

2400mg once by injection

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York